NCT04698317

Brief Summary

This clinical study aimed to evaluate the efficacy of biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors in the treatment of periodontal intra-bony defects, as compared with biodegradable gelatin/beta-tricalcium phosphate sponges alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2021

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 31, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 6, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2021

Completed
Last Updated

October 4, 2021

Status Verified

October 1, 2021

Enrollment Period

6 months

First QC Date

December 31, 2020

Last Update Submit

October 1, 2021

Conditions

Keywords

Beta-Tricalcium Phosphateregenerationconcentrated growth factors

Outcome Measures

Primary Outcomes (6)

  • gingival index

    gingival index will be recorded at baseline, 3, and 6 months at the site to be treated

    6months

  • bleeding on probing

    bleeding on probing will be recorded at baseline, 3, and 6 months at the site to be treated

    6 months

  • probing pocket depth

    probing pocket depth will be recorded at baseline, 3, and 6 months at the site to be treated

    6 months

  • clinical attachment level

    clinical attachment level will be recorded at baseline, 3, and 6 months at the site to be treated

    6 months

  • cone beam x ray measuring defect area

    defect area will be recorded at baseline, and 6 months at the site to be treated

    6 months

  • cone beam x ray measuring bone density

    bone density will be recorded at baseline, and 6 months at the site to be treated

    6 months

Study Arms (2)

beta-tricalcium phosphate plus concentrated growth factors

EXPERIMENTAL

surgery plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).

Procedure: open flap debridementOther: use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate plus concentrated growth factors

beta tricalcium phosphate alone(control group)

PLACEBO COMPARATOR

surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group),

Procedure: open flap debridementOther: use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone

Interventions

Open flap for removal of diseased periodontal tissues and necrotic cementum

Also known as: periodontal surgery
beta tricalcium phosphate alone(control group)beta-tricalcium phosphate plus concentrated growth factors

use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate incorporating Concentrated Growth Factors in Periodontal Defect

Also known as: regenerative surgery
beta-tricalcium phosphate plus concentrated growth factors

use of Biodegradable Gelatin Sponge loaded with Beta-tricalcium Phosphate alone in the Intrabony Periodontal Defect

Also known as: Regenerative surgery
beta tricalcium phosphate alone(control group)

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • systemically healthy patients were selected
  • patients who had not received any medications for the previous six months that may interfere with periodontal tissue health or healing.
  • Patients should demonstrate their ability to maintain good oral hygiene

You may not qualify if:

  • Smokers and pregnant patients.
  • Medically compromised patients and systemic conditions precluding periodontal surgery.
  • Subjects who do not comply with oral hygiene measures as evidenced in recall visits.
  • Sites with tooth mobility
  • Restoration or caries in the site to be treated or non-vital tooth
  • Restoration or caries in the site to be treated or non-vital tooth

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Malak Mohamed Shoukheba

Tanta, 020, Egypt

Location

MeSH Terms

Conditions

Chronic Periodontitis

Interventions

beta-tricalcium phosphate

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • malak m shoukheba

    Cairo University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: 40 Patients will be randomly assigned to either test or control group. 20 patients will be treated by surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone. (control group), the other 20 patients will be treated with the same surgical technique plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate prof.

Study Record Dates

First Submitted

December 31, 2020

First Posted

January 6, 2021

Study Start

January 1, 2021

Primary Completion

July 1, 2021

Study Completion

July 1, 2021

Last Updated

October 4, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations